Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.25 mg - alprazolam - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.25 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 0.5 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - alprazolam - tablets - alprazolam 1 mg - alprazolam - treatment of anxiety accompanied by depression. treatment of panic states with or without accompanying phobia.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 100 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - palivizumab, quantity: 50 mg - injection, solution - excipient ingredients: histidine; glycine; water for injections - synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd). (see clinical trials).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - palivizumab 100mg (;+overage = 122mg/vial) - injection with diluent - 100 mg - active: palivizumab 100mg (;+overage = 122mg/vial) excipient: glycine histidine mannitol nitrogen transferrin water for injection - synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age < 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - palivizumab 50mg (;+ overage = 73mg/vial) - injection with diluent - 50 mg - active: palivizumab 50mg (;+ overage = 73mg/vial) excipient: glycine histidine mannitol nitrogen water for injection - synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in children at high risk of rsv disease. safety and efficacy were established in children with bronchopulmonary dysplasia (bpd), infants with a history of prematurity (gestational age < 35 weeks at birth) and children with haemodynamically significant congenital heart disease (chd).